Literature DB >> 1708780

Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.

R Q Warren1, H Wolf, R A Zajac, R N Boswell, P Kanda, R C Kennedy.   

Abstract

We examined sera from 160 HIV-infected individuals for antibodies reactive to HIV-1 gp160 epitopes defined by seven synthetic peptides. Seropositive individuals were placed into three groups based upon levels of circulating CD4+ cells. These groups consisted of individuals with (1) more than 400 CD4+ cells, (2) 200-400 CD4+ cells, and (3) fewer than 200 CD4+ cells/mm3. The percentage of sera containing antibodies reactive with two immunodominant gp160 epitopes (a.a. 304-321 and 600-611) was unchanged between groups, regardless of CD4 cell numbers. The percentage of sera containing antibodies reactive with weakly immunogenic gp160 epitopes, such as those defined by peptides 425-448 and 846-860, declined in the groups as CD4 values decreased. Our results suggest that the patterns of antibody reactivity to gp160 epitopes change as CD4 levels decline. A narrowing of the humoral immune response to epitopes on the envelope of HIV-1 appears to occur with disease progression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708780     DOI: 10.1007/bf00918790

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  43 in total

1.  Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV.

Authors:  J A Hoxie; J D Alpers; J L Rackowski; K Huebner; B S Haggarty; A J Cedarbaum; J C Reed
Journal:  Science       Date:  1986-11-28       Impact factor: 47.728

2.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

3.  T cell recognition of HIV synthetic peptides in a natural infection.

Authors:  R D Schrier; J W Gnann; R Landes; C Lockshin; D Richman; A McCutchan; C Kennedy; M B Oldstone; J A Nelson
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

4.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Increased IgA as a predictor of development of AIDS in HIV-infected subjects.

Authors:  J J Lefrère; J M Fine; P Lambin; D Salmon; C Salmon
Journal:  Clin Chem       Date:  1988-06       Impact factor: 8.327

Review 6.  The natural history of human immunodeficiency virus infection.

Authors:  A R Lifson; G W Rutherford; H W Jaffe
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

7.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection.

Authors:  A Shafferman; J Lennox; H Grosfeld; J Sadoff; R R Redfield; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1989-02       Impact factor: 2.205

9.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus.

Authors:  J W Gnann; P L Schwimmbeck; J A Nelson; A B Truax; M B Oldstone
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

View more
  6 in total

1.  Binding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children.

Authors:  S S Prakash; Raiees Andrabi; Rajesh Kumar; S K Kabra; Rakesh Lodha; Madhu Vajpayee; Kalpana Luthra
Journal:  Viral Immunol       Date:  2011-12       Impact factor: 2.257

2.  Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.

Authors:  R Q Warren; W M Nkya; J F Shao; S A Anderson; H Wolf; C W Hendrix; P Kanda; M Wabuke; R N Boswell; R R Redfield
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

3.  Evidence of simian virus 40 exposure in a colony of captive baboons.

Authors:  Landon W Westfall; Michael H Shearer; Cynthia A Jumper; Gary L White; James F Papin; Richard Eberle; Janet S Butel; Robert K Bright; Ronald C Kennedy
Journal:  Virology       Date:  2008-05-16       Impact factor: 3.616

4.  Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression.

Authors:  R Q Warren; M T Wong; G P Melcher; S P Blatt; I Zapiola; M B Bouzas; G Muchinik; S A Anderson; R C Kennedy
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

5.  Fine specificity of the murine immune response to SV40 large tumour antigen utilizing synthetic peptides that define selected epitopes.

Authors:  R K Bright; M H Shearer; R C Kennedy
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

6.  The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study.

Authors:  Kristin Brekke; Maja Sommerfelt; Mats Ökvist; Anne Margarita Dyrhol-Riise; Dag Kvale
Journal:  BMC Infect Dis       Date:  2017-03-24       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.